Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

745 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression.
Saponaro M, Flottmann S, Eckstein M, Hommerding O, Klümper N, Corvino D, Hosni S, Schmidt A, Mönig N, Schmidt D, Ellinger J, Toma M, Kristiansen G, Bald T, Alimonti A, Ritter M, Hölzel M, Alajati A. Saponaro M, et al. Among authors: eckstein m. Sci Rep. 2023 Feb 17;13(1):2838. doi: 10.1038/s41598-023-28942-0. Sci Rep. 2023. PMID: 36801926 Free PMC article. No abstract available.
Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma.
Weyerer V, Weisser R, Moskalev EA, Haller F, Stoehr R, Eckstein M, Zinnall U, Gaisa NT, Compérat E, Perren A, Keck B, Allory Y, Kristiansen G, Wullich B, Agaimy A, Hartmann A, Bertz S. Weyerer V, et al. Among authors: eckstein m. Histopathology. 2019 Dec;75(6):865-875. doi: 10.1111/his.13958. Epub 2019 Oct 23. Histopathology. 2019. PMID: 31348552 Free article.
CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma.
Klümper N, Ralser DJ, Zarbl R, Schlack K, Schrader AJ, Rehlinghaus M, Hoffmann MJ, Niegisch G, Uhlig A, Trojan L, Steinestel J, Steinestel K, Wirtz RM, Sikic D, Eckstein M, Kristiansen G, Toma M, Hölzel M, Ritter M, Strieth S, Ellinger J, Dietrich D. Klümper N, et al. Among authors: eckstein m. J Immunother Cancer. 2021 Aug;9(8):e002949. doi: 10.1136/jitc-2021-002949. J Immunother Cancer. 2021. PMID: 34446578 Free PMC article.
C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma.
Klümper N, Schmucker P, Hahn O, Höh B, Mattigk A, Banek S, Ellinger J, Heinzelbecker J, Sikic D, Eckstein M, Strauß A, Zengerling F, Hölzel M, Zeuschner P, Kalogirou C. Klümper N, et al. Among authors: eckstein m. Clin Transl Immunology. 2021 Dec 6;10(12):e1358. doi: 10.1002/cti2.1358. eCollection 2021. Clin Transl Immunology. 2021. PMID: 34925829 Free PMC article.
C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
Klümper N, Sikic D, Saal J, Büttner T, Goldschmidt F, Jarczyk J, Becker P, Zeuschner P, Weinke M, Kalogirou C, Breyer J, Burger M, Nuhn P, Tully K, Roghmann F, Bolenz C, Zengerling F, Wirtz RM, Muders M, Kristiansen G, Bald T, Ellinger J, Wullich B, Hölzel M, Hartmann A, Erben P, Ritter M, Eckstein M. Klümper N, et al. Among authors: eckstein m. Eur J Cancer. 2022 May;167:13-22. doi: 10.1016/j.ejca.2022.02.022. Epub 2022 Mar 30. Eur J Cancer. 2022. PMID: 35366569 Free article.
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition.
Erlmeier F, Klümper N, Landgraf L, Strissel PL, Strick R, Sikic D, Taubert H, Wach S, Geppert CI, Bahlinger V, Breyer J, Ritter M, Bolenz C, Roghmann F, Erben P, Schwamborn K, Wirtz RM, Horn T, Wullich B, Hölzel M, Hartmann A, Gschwend JE, Weichert W, Eckstein M. Erlmeier F, et al. Among authors: eckstein m. Eur Urol. 2023 Feb;83(2):133-142. doi: 10.1016/j.eururo.2022.10.020. Epub 2022 Nov 10. Eur Urol. 2023. PMID: 36372626 Free article.
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, Zengerling F, Erben P, Schwamborn K, Wirtz RM, Horn T, Nagy D, Toma M, Kristiansen G, Büttner T, Hahn O, Grünwald V, Darr C, Erne E, Rausch S, Bedke J, Schlack K, Abbas M, Zschäbitz S, Schwab C, Mustea A, Adam P, Manseck A, Wullich B, Ritter M, Hartmann A, Gschwend J, Weichert W, Erlmeier F, Hölzel M, Eckstein M. Klümper N, et al. Among authors: eckstein m. Clin Cancer Res. 2023 Apr 14;29(8):1496-1505. doi: 10.1158/1078-0432.CCR-22-1764. Clin Cancer Res. 2023. PMID: 36534531 Free PMC article.
CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression.
Saponaro M, Flottmann S, Eckstein M, Hommerding O, Klümper N, Corvino D, Hosni S, Schmidt A, Mönig N, Schmidt D, Ellinger J, Toma M, Kristiansen G, Bald T, Alimonti A, Ritter M, Hölzel M, Alajati A. Saponaro M, et al. Among authors: eckstein m. Sci Rep. 2023 Jan 2;13(1):73. doi: 10.1038/s41598-022-26579-z. Sci Rep. 2023. PMID: 36593286 Free PMC article.
Reply to Jon Griffin. TIME for a Change? Multimarker Assessment of the Tumour Immune Microenvironment and Metastatic Site Biopsy to Improve Immunotherapy Response Prediction in Muscle-invasive Bladder Cancer. Eur Urol. 2023;43:143-4.
Klümper N, Hölzel M, Eckstein M. Klümper N, et al. Among authors: eckstein m. Eur Urol. 2023 Apr;83(4):e115-e116. doi: 10.1016/j.eururo.2023.01.013. Epub 2023 Jan 24. Eur Urol. 2023. PMID: 36702695 No abstract available.
745 results